Vaxart Stock Climbs After Blockbuster Q1 Revenue
Vaxart Stock Climbs After Blockbuster Q1 Revenue
Vaxart, Inc. (NASDAQ:VXRT) reported its first-quarter financial results after the bell Monday. Here's a look at the details.
Vaxart, Inc.（納斯達克股票代碼：VXRT）在週一收盤後公佈了其第一季度財務業績。以下是細節。
The Details: Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate.
詳情：Vaxart公佈的季度虧損爲每股14美分，與分析師的共識估計一致。
Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by 172.63% and representing a 223.11% increase over sales of $675,000 from the same period last year.
季度銷售額爲218.1萬美元，比分析師普遍預期的80萬美元高出172.63％，比去年同期的67.5萬美元銷售額增長了223.11％。
The company said it is preparing for a 10,000-subject, Phase 2b clinical study evaluating its oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator.
該公司表示，正在爲一項受試者爲10,000名受試者的2b期臨床研究做準備，評估其口服藥丸XBB COVID-19 候選疫苗對照已批准的mRNA疫苗比較器。
The preparations are being supported by a U.S. Biomedical Advanced Research and Development Authority (BARDA) contract for $9.27 million as part of BARDA's "Project NextGen" initiative. Vaxart anticipates initiating the Phase 2b trial as early as the second quarter of 2024.
作爲BARDA “下一代項目” 計劃的一部分，美國生物醫學高級研究與發展局（BARDA）簽訂的價值927萬美元的合同爲這些準備工作提供了支持。Vaxart預計最早將在2024年第二季度啓動2b期試驗。
Vaxart announced positive topline results from the Phase 1 clinical trial evaluating its oral pill bivalent norovirus candidate in lactating mothers in April.
Vaxart於4月宣佈了評估其在哺乳期母親中服用二價諾如病毒候選藥物的1期臨床試驗的積極結果。
The company said it plans to meet with the U.S. Food and Drug Administration (FDA) in mid-2024 to discuss data on correlates of protection, and these data will inform potential next steps, such as potentially conducting a Phase 2b study and potentially a GII.4 challenge study.
該公司表示，計劃在2024年中期與美國食品藥品監督管理局（FDA）會面，討論保護相關性的數據，這些數據將爲潛在的下一步措施提供信息，例如可能進行2b期研究和可能的GII.4挑戰研究。
"We are pleased that we achieved an important milestone in our norovirus clinical program, delivering positive topline results from the Phase 1 trial of our oral pill bivalent norovirus candidate focused on lactating mothers," said Steven Lo, Vaxart's CEO.
Vaxart首席執行官Steven Lo表示：“我們很高興我們在諾如病毒臨床項目中取得了重要的里程碑，我們的口服避孕藥二價諾如病毒候選藥物的1期試驗取得了積極的結果。”
"We look forward to additional data from this study that will further inform future pediatric studies for this indication. We have also made significant progress and remain on track to initiate a Phase 2b study evaluating our XBB COVID-19 vaccine candidate as early as this quarter."
“我們期待這項研究的更多數據，這將進一步爲該適應症的未來兒科研究提供信息。我們還取得了重大進展，並有望最早在本季度啓動一項評估我們的 XBB COVID-19 候選疫苗的 2b 期研究。”
Related News: GameStop Leads Roaring Rally: What's Going On With Meme Stocks?
相關新聞： GameStop 引領激烈反彈：模因股票怎麼了？
VXRT Price Action: According to Benzinga Pro, Vaxart shares are up 12.24% after-hours at 92 cents after gaining 16.31% during regular trading Monday.
VXRT價格走勢：根據Benzinga Pro的數據，Vaxart股價在週一的常規交易中上漲了16.31％，盤後上漲了12.24％，至92美分。
Photo: Shutterstock
照片：Shutterstock
譯文內容由第三人軟體翻譯。